ZINC OF IRELAND NL

ASX Announcement

29 January 2019

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 & NOTICE UNDER ASX LISTING RULE 3.10.5A

This notice is given by Zinc of Ireland NL (ASX: ZMI) ("ZMI" or "Company") pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Corporations Act").

The Company has raised \$2,425,000 by the issue of 485,000,000 fully paid ordinary shares ("Shares") at \$0.005 per share, pursuant to a placement announced to the ASX on 29 January 2019 to Dundee Resources Limited, an investor qualifying under section 708 of the Corporations Act.

In accordance with section 708A(5)(e) of the Corporations Act, the Company gives notice that:

- 1. the Company issued the Shares without disclosure under part 6D.2 of the Corporations Act;
- 2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and section 674 of the Corporations Act; and
- 3. as at the date of this notice, there is no "excluded information" (as defined in sections 708A(7) and 708A(8) of the Corporations Act).

As required by ASX Listing Rule 3.10.5A, in respect of the issue of 193,145,718 Shares under the Company's placement capacity ASX Listing Rule 7.1A, the Company states that:

1. (a) The dilutive effect of the Placement on existing shareholders of the Company is as follows:

	Shares	Dilution
Shares on issue prior to Placement	1,945,695,208	
Shares issued under LR7.1 capacity	291,854,282	12.01%
Shares issued under LR7.1A capacity	193,145,718	7.95%
Total shares on issue post Placement	2,430,695,208	
Total dilution effect		19.96%

(b) The percentage of the post Placement issued capital held (in aggregate) relating to shares issued under the Placement is as follows:

Pre-Placement shareholders who did not participate in Placement	0%
Pre-Placement shareholders who did participate in Placement	0%
Participants in Placement who were not previously shareholders	100%

2. The Company considered the 7.1A Placement as the most efficient and expedient method for raising the funds required by the Company particularly given that the price of the issue was at a 25% premium to the market price and the issue was made entirely to one party, namely, Dundee Resources Limited;



- 3. There was no underwriting.
- 4. In connection with the placement of \$2,425,000 (comprised by 291,854,282 fully paid ordinary shares issued under ASX Listing Rule 7.1 and the 193,145,718 fully paid ordinary shares issued under ASX Listing Rule 7.1A) a cash fee of 6% of that amount is payable to Goodman & Company, Investment Counsel Inc. In addition, the Company has agreed to issue to Goodman & Company, Investment Counsel Inc approximately 30,000,000 unlisted broker options, exercisable at \$0.01 and expiring 2 years from the date of issue, subject to obtaining shareholder approval at an upcoming general meeting of the Company.

Yours faithfully,

Patrick Corr

Executive Director Zinc of Ireland NL

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.


Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Linc of	r Ireland NL				
ABN					
23 124 1	140 889				
We (th	We (the entity) give ASX the following information.				
	1 - All issues st complete the relevant sections (attach	sheets if there is not enough space).			
1	*Class of *securities issued or to be issued	Fully paid ordinary shares			
2	Number of *securities issued or	485,000,000			
	to be issued (if known) or maximum number which may be issued				
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares			

Name of entity

⁺ See chapter 19 for defined terms.

Do the *securities rank equally Yes, the shares rank equally in all respects 4 from the date of issue with the existing in all respects from the date of allotment with an existing +class quoted fully paid ordinary shares of the of quoted *securities? Company. If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.005 per share 5 6 Purpose of the issue Issued pursuant to placement. (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Yes Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 30 November 2018 resolution under rule 7.1A was passed 6c Number of +securities issued 291,854,282 without security holder approval under rule 7.1 6d Number of +securities issued 193,145,718 with security holder approval under rule 7.1A



-

6f Number of securities issued under an exception in rule 7.2

-

6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

Yes 15 day VWAP = \$0.004 75% = \$0.003 Date of issue 25 January 2019

(Source: Yahoo Finance)

6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements.

-

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1A 1,423,803 (Refer to Annexure 1)

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

25 January 2019

8 Number and *class of all *securities quoted on ASX (*including* the securities in section 2 if applicable)

Number	⁺ Class
2,430,695,208	Fully paid ordinary Shares
1,159,035	Partly paid ordinary Shares
1,057,556,300	Options exercisable at \$0.015 each and expiring 21 July 2021

⁺ See chapter 19 for defined terms.

9 Number and *class of all
*securities not quoted on ASX
(including the securities in
section 2 if applicable)

Number	+Class
129,800,000	Unlisted options exercisable at \$0.02 each and expiring on 30 April 2020
326,333,333	Unlisted options exercisable at \$0.04 each and expiring 21 July 2021
7,000,000	Unlisted options exercisable at \$0.06 each and expiring 30 September 2021
750,000	Class C Performance Rights expiring 26 May 2021
750,000	Class D Performance Rights expiring 26 May 2021
1,300,000	Class E Performance Rights expiring 26 May 2021
50,000,000	Unlisted options exercisable at \$0.015 and expiring 11 July 2020
15,000,000	Unlisted Class A director options exercisable at \$0.015 and expiring 11 July 2021
15,000,000	Unlisted Class B director options exercisable at \$0.02 and expiring 11 July 2021

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Despatch date	
		1

You need	d only co	omplete this section if you are applying for quotation of securities
34	Type (tick	of securities one)
(a)		Securities described in Part 1
(b)		All other securities
		Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pai employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertibe securities
Entitie	s that	have ticked box 34(a)
Additi	onal s	ecurities forming a new class of securities
Tick to	indicate	you are providing the information or documents
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for the additional *securities
Entitie	s that	have ticked box 34(b)
38		per of securities for which ation is sought
39		of *securities for which ition is sought

Part 3 - Quotation of securities

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		I.	
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		

Appendix 3B Page 8 01/08/2012

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 29 January 2019 (Company secretary)

Print name: Keith Bowker

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base fig capacity is calculated	gure from which the placement	
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,404,695,208	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	351,000,000 Ordinary Shares 190,000,000 Ordinary shares	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-	
"A"	1,945,695,208	

Appendix 3B Page 10 01/08/2012

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15 [Note: this value cannot be changed]		
Multiply "A" by 0.15	291,854,282		
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule		
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	291,854,282 Ordinary Shares		
• Under an exception in rule 7.2			
• Under rule 7.1A			
 With security holder approval under rule 7.1 or rule 7.4 			
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
"C"	291,854,282		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	291,854,282		
Note: number must be same as shown in Step 2			
Subtract "C"	291,854,282		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	- [Note: this is the remaining placement capacity under rule 7.1]		

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	194,569,521
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	193,145,718 Ordinary Shares
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
separate inte items	

Appendix 3B Page 12 01/08/2012

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	194,569,521
Note: number must be same as shown in Step 2	
Subtract "E"	193,145,718
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	1,423,803
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.